GlassScriptPhysician profile
Ritesh Patil
NPI 1699892695
$2,291.33
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $1,229 · 2021: $249 · 2022: $366 · 2023: $128 · 2024: $30.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $329.69 | 2019-2022 | |
| Seagen INC. | $248.73 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $209.19 | 2019-2022 | |
| Janssen Biotech, INC. | $171.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $165.59 | 2019-2022 | |
| Daiichi Sankyo INC. | $117.09 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $114.17 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $102.12 | 2019-2020 | |
| Abbvie INC. | $81.38 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.37 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $70.67 | 2019-2023 | Imbruvica |
| Celgene Corporation | $67.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $57.58 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.69 | 2019-2020 | |
| Amgen INC. | $49.50 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.99 | 2019-2020 | |
| Foundation Medicine, INC. | $42.04 | 2020-2023 | |
| Genzyme Corporation | $27.51 | 2022 | |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Aptima, Thinprep 2000 Processor |
| Regeneron Healthcare Solutions, INC. | $21.63 | 2022 | |
| Taiho Oncology, INC. | $21.14 | 2019 | |
| Incyte Corporation | $20.22 | 2019 | |
| Astellas Pharma US INC | $19.78 | 2020 | |
| Global Blood Therapeutics, INC. | $19.66 | 2020 | |
| Emmaus Medical, INC. | $18.44 | 2019 | |
| Genentech USA, INC. | $17.99 | 2020 | |
| Array Biopharma INC | $17.67 | 2020 | |
| Eisai INC. | $12.70 | 2020 | |
| Kite Pharma, INC. | $12.34 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritesh Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.